Payment overview · 2025
General Payments
$497.98
16 reported records · 7 companies
Healthcare provider profile · identity verified
George B. Hughes, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BURNT HILLS, NY · NPI 1720054380
Verified facts
What the public records show
CMS Open Payments records show George B. Hughes, M.D. received $497.98 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zubsolv by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $177.47 | 35.6% | 4 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $140.48 | 28.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.54 | 15.0% | 4 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $38.09 | 7.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.32 | 6.3% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $18.73 | 3.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.35 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $497.98 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $177.47 | 4 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $140.48 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.54 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.59 | 3 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $38.09 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.32 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 198 | 29 |
| Lisinopril | Lisinopril | 177 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 153 | 36 |
| Metformin Hcl | Metformin Hcl | 129 | 29 |
| Omeprazole | Omeprazole | 115 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 108 | 22 |
| Clonidine Hcl | Clonidine Hcl | 101 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 17 |
| Torsemide | Torsemide | 83 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 82 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 12 |
| Famotidine | Famotidine | 74 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 12 |
| Propranolol Hcl | Propranolol Hcl | 68 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Clonazepam | Clonazepam | 65 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 17 |
| Ibuprofen | Ibuprofen | 62 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 16 |
| Trazodone Hcl | Trazodone Hcl | 59 | 13 |
| Mirtazapine | Mirtazapine | 54 | 11 |
| Potassium Chloride | Potassium Chloride | 54 | 12 |
| Losartan Potassium | Losartan Potassium | 51 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 12 |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Jardiance | Empagliflozin | 43 | suppressed |
| Alprazolam | Alprazolam | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Lactulose | Lactulose | 31 | 11 |
| Atenolol | Atenolol | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Furosemide | Furosemide | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $497.98 · 16 records | ABBVIE INC. | AIRSUPRA, BRIXADI, QULIPTA, SPRAVATO, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, Zubsolv | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Zubsolv play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error